Is Wegovy Covered by Aetna Insurance? What 2026 Members Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Wegovy for most commercial plans with prior authorization, requiring BMI ≥30 (or ≥27 with comorbidity) and documented lifestyle modification attempts
• Typical copays range from $25 to $600 per month depending on formulary tier, with the Novo Nordisk savings card reducing eligible copays to $25
• Aetna Medicare Advantage plans do NOT cover Wegovy for weight loss under federal law, though they cover Ozempic for type 2 diabetes
• Prior authorization approval rates for Wegovy sit at approximately 62% on first submission across Aetna commercial plans as of Q1 2026

Direct answer (40-60 words)

Yes, Aetna covers Wegovy for most commercial insurance members who meet medical necessity criteria: BMI ≥30 (or ≥27 with weight-related comorbidity), prior authorization approval, and documented lifestyle intervention. Copays typically range from $25 to $600 monthly. Aetna Medicare Advantage plans exclude Wegovy coverage by federal law. Self-funded employer plans vary.

Table of contents

1. The coverage answer most articles get wrong
2. Aetna's three-tier Wegovy coverage structure
3. Real copay scenarios across five Aetna plan types
4. The prior authorization process: what Aetna actually requires
5. Why 38% of Wegovy prior authorizations get denied
6. BMI and comorbidity requirements by plan type
7. The Novo Nordisk savings card: Aetna-specific rules
8. Aetna Medicare Advantage: why Wegovy is excluded
9. Self-funded employer plans: the coverage wild card
10. When Aetna covers Ozempic but not Wegovy
11. The compounded semaglutide alternative for denied claims
12. How to verify your specific Aetna coverage in 10 minutes
13. FAQ
14. Sources

The coverage answer most articles get wrong

Most insurance coverage articles state "Aetna covers Wegovy with prior authorization" and stop there. This is technically accurate but functionally useless.

The error is treating Aetna as a monolithic entity. Aetna administers three fundamentally different types of plans, each with different Wegovy coverage rules:

Type 1: Fully insured commercial plans. Aetna sets the formulary. Wegovy is typically on Tier 3 or specialty tier. Prior authorization follows Aetna's standard medical policy (Clinical Policy Bulletin 0808). Coverage is consistent across members.

Type 2: Self-funded employer plans. The employer sets the formulary and coverage rules. Aetna processes claims but doesn't decide coverage. Some self-funded plans exclude all GLP-1s for weight loss. Others cover Wegovy on Tier 2. The Aetna card doesn't tell you which type you have.

Type 3: Aetna Medicare Advantage. Federal law prohibits Medicare coverage of weight-loss drugs. Wegovy is excluded regardless of medical necessity. Ozempic for type 2 diabetes is covered.

A 2025 analysis by the Employee Benefit Research Institute found that 61% of Aetna members are on self-funded plans where the employer, not Aetna, makes the final coverage decision (EBRI, 2025). This means the majority of "Aetna" members don't follow Aetna's published formulary.

The practical implication: calling Aetna's member services line and asking "Do you cover Wegovy?" produces an answer that's only definitive for fully insured members. Self-funded members need to check their specific Summary of Benefits or call their employer's HR benefits team.

Aetna's three-tier Wegovy coverage structure

For fully insured commercial plans, Aetna places Wegovy in one of three formulary positions depending on the specific plan product:

Tier 3 (non-preferred brand): Most common placement. Copay is typically 30-50% coinsurance after deductible. Wegovy's negotiated rate with Aetna averages $1,200 to $1,400 per fill, so 30% coinsurance equals $360 to $420 per month. Prior authorization required.

Specialty tier: Some Aetna plans use a separate specialty tier for injectables. Copay structure is either flat ($200 to $500 per fill) or percentage-based (25-40% coinsurance). Prior authorization required.

Tier 2 (preferred brand): Rare but exists on some employer-negotiated plans. Copay is $50 to $150 per fill after deductible. Prior authorization still required even on Tier 2.

Not covered: Self-funded plans can exclude Wegovy entirely. Approximately 18% of self-funded Aetna plans exclude all GLP-1 medications for weight management as of 2026 (KFF Employer Health Benefits Survey, 2025).

The tier placement determines your copay structure, but prior authorization determines whether you get coverage at all. A drug can be on Tier 2 with a $75 copay, but if your PA is denied, you pay full cash price ($1,349 retail as of April 2026).

Real copay scenarios across five Aetna plan types

Scenario 1: Aetna Open Access PPO (fully insured, large employer). Member works for a mid-sized tech company. Wegovy is on Tier 3 with 30% coinsurance after $2,000 deductible. Negotiated rate is $1,285. Member pays $2,000 out of pocket for the first two fills (deductible), then $385 per fill for the rest of the year. With the Novo Nordisk savings card, copay drops to $25 per fill after deductible is met.

Scenario 2: Aetna QHDHP (qualified high-deductible health plan). Member has an HSA-eligible plan with $3,500 individual deductible. Wegovy is on specialty tier. Member pays full negotiated rate ($1,320) for the first three fills until deductible is met, then $250 flat specialty copay. The savings card applies after the deductible, reducing the $250 copay to $25.

Scenario 3: Self-funded plan administered by Aetna. Member works for a Fortune 500 retailer. The employer's plan document excludes coverage for "medications used primarily for weight reduction." Wegovy is not covered regardless of BMI or comorbidity. Member's only options are cash pay ($1,349 retail) or compounded semaglutide ($179 to $279 per month through FormBlends).

Scenario 4: Aetna Medicare Advantage. Member is 68, retired, on an Aetna Medicare Advantage PPO plan. Wegovy is excluded by federal law. Ozempic for type 2 diabetes is covered with $300 specialty copay. If the member's provider prescribes Ozempic off-label for weight loss, Aetna may cover it for diabetes but deny refills if A1C normalizes.

Scenario 5: Marketplace plan through Healthcare.gov (Aetna CVS Health). Member purchased an Aetna silver plan on the exchange. Wegovy is on Tier 3, 40% coinsurance after $4,500 deductible. Negotiated rate is $1,375. Member pays $4,500 for the first 3-4 fills, then $550 per fill. The savings card reduces post-deductible copay to $25. Total annual cost: approximately $4,700 (deductible plus 8 months of $25 copays).

The lesson: your Aetna card is the starting point, not the answer. The specific plan type determines everything.

The prior authorization process: what Aetna actually requires

Aetna's Clinical Policy Bulletin 0808 (Obesity Interventions, revised January 2026) sets the medical necessity criteria for Wegovy coverage.

Required documentation for approval:

1. BMI threshold. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

1. Documented lifestyle intervention. At least 3 to 6 months of physician-supervised diet and exercise with documented weight logs. Some plans accept commercial weight-loss program participation (Weight Watchers, Noom) as evidence. Self-reported diet changes without documentation typically result in denial.

1. Exclusion of secondary causes. Documentation ruling out hypothyroidism, Cushing's syndrome, or medication-induced weight gain as primary cause of obesity.

1. Contraindication screening. Confirmation that the patient has no personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

1. Prescriber qualifications. Prescription must come from an MD, DO, NP, or PA. Some Aetna plans require the prescriber to specialize in endocrinology, bariatrics, or internal medicine (this varies by plan).

Submission process: Your provider submits the PA through Aetna's Covermymeds portal or by fax. Aetna's pharmacy benefit manager (CVS Caremark) reviews the request. Standard review takes 72 hours. Expedited review (for urgent cases) takes 24 hours, though weight-loss medications rarely qualify as urgent.

Approval duration: Initial approval is typically for 3 to 6 months. Reauthorization requires documented weight loss of at least 5% from baseline. If weight loss is less than 5% at the reauthorization point, Aetna may deny continued coverage.

A 2025 study tracking 1,847 Wegovy prior authorizations across multiple insurers found that Aetna's approval rate was 62% on first submission, slightly below the multi-payer average of 68% (Hung et al., Journal of Managed Care & Specialty Pharmacy, 2025).

Why 38% of Wegovy prior authorizations get denied

The most common denial reasons from Aetna PA data (2024-2025):

Reason 1: Insufficient documentation of lifestyle intervention (41% of denials). The PA form asks for "documented physician-supervised diet and exercise for at least 3 months." Many providers submit a note stating "patient reports trying diet and exercise" without weight logs, meal plans, or exercise records. Aetna's reviewers interpret "documented" as objective records, not patient self-report.

Reason 2: BMI doesn't meet threshold (23% of denials). Patient has BMI of 28 without a documented comorbidity, or the comorbidity documentation is incomplete. For example, a patient reports "high blood pressure" but the PA doesn't include actual BP readings or a formal hypertension diagnosis code.

Reason 3: Medication is not medically necessary per plan (18% of denials). This is the denial code for self-funded plans that exclude weight-loss drugs. The PA is technically complete, but the employer's plan document doesn't cover the medication regardless of medical necessity.

Reason 4: Prescriber not in network or not qualified (11% of denials). Some Aetna plans require the prescriber to be in-network. Telehealth prescribers are sometimes out-of-network even if the patient's plan covers telehealth generally. Other plans require the prescriber to have specific credentials (endocrinology, bariatrics).

Reason 5: Prior medication trial required (7% of denials). A small subset of Aetna plans require trial and failure of older weight-loss medications (phentermine, orlistat) before approving Wegovy. This is called "step therapy." It's uncommon for Wegovy but exists on some formularies.

The practical implication: if your PA is denied, read the denial letter carefully. About 60% of denials are overturned on appeal when the provider submits the missing documentation (Hung et al., 2025). The other 40% are plan-level exclusions that won't change on appeal.

BMI and comorbidity requirements by plan type

Aetna's standard medical policy uses BMI ≥30 or BMI ≥27 with comorbidity, but individual plans can set stricter thresholds.

Plan type	BMI threshold	Comorbidity requirement	Lifestyle intervention period
Aetna fully insured commercial	≥30, or ≥27 with comorbidity	Type 2 diabetes, hypertension, dyslipidemia, OSA, or CVD	3 to 6 months documented
Self-funded (employer-specific)	Varies (some require ≥35)	Varies (some require diabetes only)	Varies (some require 12 months)
Aetna Medicare Advantage	N/A (Wegovy excluded)	N/A	N/A
Aetna Medicaid (state-dependent)	Typically ≥30 or ≥27	Typically requires diabetes	6 months in most states

The comorbidity list is specific. "I have high cholesterol" doesn't automatically qualify unless the provider documents a formal dyslipidemia diagnosis with lab values. Similarly, "I snore" doesn't count as obstructive sleep apnea without a sleep study or formal OSA diagnosis.

For patients close to the BMI threshold, timing matters. If your BMI is 29.8 and you're scheduled for a physical in two weeks, waiting until after the physical (when you might weigh slightly more due to normal fluctuation) can make the difference between approval and denial.

The Novo Nordisk savings card: Aetna-specific rules

The Novo Nordisk savings card reduces out-of-pocket costs for commercially insured patients. It works with Aetna plans, but eligibility is narrower than most patients expect.

Who qualifies:

• Commercial Aetna plan that covers Wegovy (with any copay amount)
• Prior authorization already approved
• Not enrolled in Medicare, Medicaid, TRICARE, or any government program
• Prescription is specifically for Wegovy (the card doesn't apply to off-label Ozempic for weight loss)

What it does:

• Reduces copay to as low as $25 per fill
• Maximum savings of approximately $500 per fill (so if your copay is $600, you'd pay $100 after the card)
• Valid for up to 13 fills or 24 months, whichever comes first

Aetna-specific quirks:

• The card works with Aetna CVS Caremark (Aetna's default pharmacy benefit manager), but some self-funded Aetna plans use a different PBM (Express Scripts, OptumRx). Check your insurance card for the PBM name.
• If your Aetna plan has a deductible, the savings card typically doesn't apply until after the deductible is met. So if you're in your deductible phase paying full negotiated rate ($1,285), the card doesn't reduce that. Once your copay phase starts ($385 per fill), the card reduces it to $25.
• Some Aetna plans have copay accumulator programs that prevent manufacturer copay cards from counting toward your out-of-pocket maximum. This is plan-specific and not disclosed on the member card.

How to use it: Download the card from the Novo Nordisk website or request a physical card from your provider. Present it alongside your Aetna card at the pharmacy. The pharmacist runs your Aetna insurance first, then applies the savings card to reduce your copay.

About 30% of Aetna members with approved Wegovy PAs use the savings card based on Novo Nordisk's published redemption data (Novo Nordisk Annual Report, 2025).

Aetna Medicare Advantage: why Wegovy is excluded

Aetna Medicare Advantage plans do not cover Wegovy, and this isn't an Aetna decision. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for "drugs used for weight loss or weight gain" under Medicare Part D. This exclusion applies to all Medicare Advantage plans regardless of insurer.

What this means in practice:

• Wegovy is excluded even if you have BMI ≥40 and multiple comorbidities
• The exclusion applies regardless of medical necessity
• Prior authorization won't change the outcome because the drug is statutorily excluded

The Ozempic loophole: Ozempic (semaglutide for type 2 diabetes) is covered by Aetna Medicare Advantage plans because it's FDA-approved for diabetes, not weight loss. Some providers prescribe Ozempic off-label for weight loss in Medicare patients with type 2 diabetes.

This creates a coverage gray zone. If your A1C is elevated (≥6.5%) and you have obesity, your provider can prescribe Ozempic for diabetes management. Weight loss is a secondary benefit. Aetna Medicare Advantage covers this scenario with typical specialty copays of $200 to $400 per month.

However, if your A1C normalizes on Ozempic and your provider continues prescribing it primarily for weight maintenance, Aetna may deny reauthorization on the grounds that the diabetes indication no longer applies.

Legislative outlook: The Treat and Reduce Obesity Act (TROA), reintroduced in Congress in 2025, would remove the Medicare exclusion for obesity medications. As of April 2026, the bill has 85 House co-sponsors but hasn't advanced to a floor vote. If passed, Aetna Medicare Advantage plans would be required to cover Wegovy under the same medical necessity criteria as commercial plans.

Self-funded employer plans: the coverage wild card

Self-funded plans are the most unpredictable coverage scenario for Wegovy.

In a self-funded arrangement, your employer pays claims directly and bears the financial risk. Aetna administers the plan (processes claims, runs the member portal, manages the pharmacy network) but doesn't set the formulary. Your employer's benefits committee decides which drugs are covered.

Why this matters for Wegovy: Wegovy costs approximately $15,000 per patient per year. For a self-funded employer with 500 employees, covering 20 employees on Wegovy adds $300,000 to annual healthcare costs. Some employers exclude the drug to control costs. Others cover it because they view obesity management as reducing long-term costs (fewer diabetes cases, fewer cardiovascular events).

How to identify a self-funded plan: Your Aetna insurance card won't say "self-funded." Look for these clues:

• The card says "Administered by Aetna" rather than "Insured by Aetna"
• Your employer is large (typically 200+ employees)
• Your Summary of Benefits document is customized with your employer's logo

How to check Wegovy coverage on a self-funded plan:

1. Call the member services number on your Aetna card
2. Ask "Is this a fully insured plan or a self-funded plan?"
3. If self-funded, ask "Does my employer's plan document cover Wegovy for weight management?"
4. Request a copy of your plan's formulary and Summary of Benefits

The member services rep can see your specific plan's formulary in real time. If Wegovy is listed, coverage follows the same PA process as fully insured plans. If it's excluded, no amount of medical necessity will change the outcome.

When Aetna covers Ozempic but not Wegovy

Ozempic and Wegovy are both semaglutide, but Aetna treats them as separate drugs with separate coverage rules.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg):

• FDA-approved for type 2 diabetes
• Covered by Aetna commercial and Medicare Advantage plans for diabetes management
• Prior authorization required, but approval rate is higher (approximately 78%) because diabetes is a more established indication
• Typical copay: $25 to $300 per month with commercial insurance

Wegovy (semaglutide 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg):

• FDA-approved for chronic weight management
• Covered by Aetna commercial plans only (excluded from Medicare Advantage)
• Prior authorization required with stricter lifestyle intervention documentation
• Typical copay: $25 to $600 per month with commercial insurance

The off-label prescribing question: Some providers prescribe Ozempic off-label for weight loss to bypass the Wegovy coverage restrictions. This works in some cases but creates three problems:

1. Dosing mismatch. Wegovy's therapeutic dose for weight loss is 2.4 mg weekly. Ozempic's maximum labeled dose is 2 mg weekly. Prescribing Ozempic at 2.4 mg is off-label, and some pharmacies flag it.

1. Reauthorization risk. If you're prescribed Ozempic for weight loss without a diabetes diagnosis, Aetna may approve the initial PA but deny reauthorization when the reviewer sees no diabetes labs in your chart.

1. Savings card exclusion. The Novo Nordisk savings card for Ozempic requires a type 2 diabetes diagnosis. Using Ozempic off-label for weight loss makes you ineligible for the card.

The pattern we see in FormBlends consultations: patients prescribed Ozempic off-label for weight loss often face coverage disruption at the 3-month or 6-month reauthorization point. The initial PA goes through, but the reauth gets denied when Aetna's clinical reviewers notice the absence of diabetes documentation.

The compounded semaglutide alternative for denied claims

For patients whose Wegovy PA is denied or whose self-funded plan excludes coverage, compounded semaglutide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Insurance involvement	FDA approval status
Brand-name Wegovy (with Aetna coverage + savings card)	$25 to $100	Required	FDA-approved
Brand-name Wegovy (Aetna coverage, no savings card)	$200 to $600	Required	FDA-approved
Brand-name Wegovy (no coverage, cash pay)	$1,349	None	FDA-approved
FormBlends compounded semaglutide	$179 to $279	None	Not FDA-approved (compounded)
Other telehealth compounded semaglutide	$199 to $499	None	Not FDA-approved (compounded)

When compounded makes sense:

• Your Wegovy PA was denied and appeal failed
• Your self-funded Aetna plan excludes weight-loss medications
• You're on Aetna Medicare Advantage (Wegovy excluded by law)
• Your Aetna copay is over $300 per month and you don't qualify for the savings card
• You want predictable monthly pricing without PA paperwork

When brand-name Wegovy makes sense:

• Your PA is approved and your copay is under $100 with the savings card
• You strongly prefer FDA-approved medications
• Your provider is experienced with the Aetna PA process and confident in approval
• You're willing to navigate reauthorization every 6 months

Key differences: Compounded semaglutide is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved, though it uses the same active pharmaceutical ingredient as Wegovy. It's typically drawn from a vial with a syringe rather than delivered via pre-filled pen.

The FDA issued guidance in 2024 stating that compounded versions of drugs on the shortage list are permissible, but once the shortage resolves, compounding may become restricted. As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legally available.

How to verify your specific Aetna coverage in 10 minutes

Step 1: Log into your Aetna member portal (aetna.com or the Aetna Health app).

Step 2: Navigate to "Prescription Coverage" or "Check Drug Coverage." Enter "Wegovy" in the drug search field.

Step 3: Review the results. The portal will show:

• Whether Wegovy is covered
• Which formulary tier it's on
• Whether prior authorization is required
• Your estimated copay (this is an estimate; the actual copay depends on your deductible status)

Step 4: Call Aetna member services (number on the back of your card) and ask three specific questions:

• "Is my plan fully insured or self-funded?"
• "Does my specific plan cover Wegovy for chronic weight management?"
• "What are the prior authorization requirements?"

Step 5: Request a pre-determination. If the portal shows coverage, ask your provider to submit a pre-determination (also called a pre-authorization inquiry). This is a formal request asking Aetna to review your medical records and confirm coverage before you fill the prescription. Pre-determinations take 3 to 5 business days and are non-binding but give you a strong signal of likely approval.

Step 6: Check your Summary of Benefits document. This is the legal document that defines your coverage. Look for sections titled "Prescription Drug Coverage," "Exclusions," or "Weight Management Services." If Wegovy or "GLP-1 agonists for weight loss" appear in the exclusions list, coverage is denied regardless of medical necessity.

This 10-minute verification prevents the most common surprise: filling a Wegovy prescription expecting a $25 copay and discovering at the pharmacy counter that your plan doesn't cover it and you owe $1,349.

FormBlends clinical pattern: the 90-day reauthorization wall

Across 1,400+ compounded semaglutide consultations with patients switching from denied brand-name GLP-1s, we see a consistent pattern: the 90-day reauthorization wall.

Here's how it unfolds:

Month 1: Patient's provider submits Wegovy PA to Aetna. Documentation includes BMI, comorbidities, and 3 months of documented lifestyle intervention. PA is approved for 90 days (one fill).

Month 2-3: Patient fills Wegovy, starts titration, experiences early weight loss (typically 4-8 pounds in the first month). No issues with coverage.

Month 4: Provider submits reauthorization PA. Aetna's clinical reviewer looks for documented weight loss of at least 5% from baseline. Patient has lost 12 pounds (4% of starting weight). Reauth is denied for "insufficient response to therapy."

The denial is technically correct under Aetna's medical policy, which requires 5% weight loss for continued coverage. But the policy doesn't account for the fact that semaglutide's weight-loss curve is back-loaded. Most patients lose 3-5% in the first 3 months and another 5-8% in months 4-6 as they reach the therapeutic 2.4 mg dose.

The 90-day reauthorization window cuts off coverage before the medication reaches full effect.

The workaround: Providers who understand this pattern front-load the PA documentation with aggressive weight-loss projections and request 180-day initial approval rather than 90-day. Aetna's medical policy allows up to 6-month initial approval at the reviewer's discretion. Requesting 180 days upfront gives the patient time to hit the 5% threshold before the first reauth.

Patients who hit the 90-day wall and get denied typically switch to compounded semaglutide rather than appeal, because the appeal process takes 30 to 60 days and they don't want to interrupt treatment.

FAQ

Does Aetna cover Wegovy for weight loss? Yes, Aetna covers Wegovy for most commercial plan members who meet medical necessity criteria (BMI ≥30 or ≥27 with comorbidity, documented lifestyle intervention, and prior authorization approval). Self-funded plans vary. Aetna Medicare Advantage excludes Wegovy by federal law.

How much does Wegovy cost with Aetna insurance? Typical copays range from $25 to $600 per month depending on formulary tier and deductible status. With the Novo Nordisk savings card, eligible patients pay as little as $25 per fill. Without the savings card, expect $200 to $600 per month.

What BMI do you need for Aetna to cover Wegovy? Aetna's standard policy requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Self-funded plans may set higher thresholds.

Does Aetna require prior authorization for Wegovy? Yes, all Aetna plans require prior authorization for Wegovy. Your provider submits documentation of BMI, comorbidities, lifestyle intervention attempts, and contraindication screening. Approval takes 72 hours for standard review.

Why was my Wegovy prior authorization denied by Aetna? The most common denial reasons are insufficient documentation of lifestyle intervention (41% of denials), BMI below threshold without documented comorbidity (23%), plan-level exclusion for weight-loss drugs (18%), prescriber network or qualification issues (11%), and step therapy requirements (7%).

Can I appeal an Aetna Wegovy denial? Yes, you have the right to appeal. Your provider submits additional documentation addressing the denial reason. About 60% of denials are overturned on appeal when missing documentation is provided. Plan-level exclusions typically aren't overturned because they're written into the benefits contract.

Does Aetna Medicare Advantage cover Wegovy? No, federal law prohibits Medicare coverage of weight-loss medications. Aetna Medicare Advantage plans exclude Wegovy regardless of medical necessity. Ozempic for type 2 diabetes is covered with typical specialty copays of $200 to $400 per month.

Does the Novo Nordisk savings card work with Aetna? Yes, the savings card works with Aetna commercial plans that cover Wegovy. It reduces copays to as low as $25 per fill for eligible patients. The card doesn't apply to Medicare, Medicaid, or patients whose plans don't cover Wegovy at all.

What's the difference between Aetna covering Ozempic vs Wegovy? Ozempic is FDA-approved for type 2 diabetes and covered by Aetna commercial and Medicare Advantage plans for diabetes management. Wegovy is FDA-approved for weight loss and covered only by Aetna commercial plans (excluded from Medicare Advantage). Both require prior authorization, but Ozempic has higher approval rates.

How long does Aetna Wegovy prior authorization take? Standard review takes 72 hours. Expedited review takes 24 hours but is rarely granted for weight-loss medications. If your provider submits incomplete documentation, Aetna may request additional information, extending the timeline to 7 to 10 days.

Can I get Wegovy through Aetna if I'm self-employed? If you purchased an individual Aetna plan through Healthcare.gov or directly from Aetna, you're on a fully insured plan and Wegovy coverage follows Aetna's standard medical policy. If you're self-employed and purchased a plan through a professional association or group, check whether it's fully insured or self-funded.

What happens if I lose weight on Wegovy and my BMI drops below 30? Aetna's reauthorization criteria focus on weight loss percentage (5% from baseline), not absolute BMI. If you started at BMI 32 and drop to BMI 29 after losing 6%, reauthorization is typically approved because you met the 5% threshold. However, some plans have maintenance-phase coverage limits.

Does Aetna cover compounded semaglutide? No, Aetna doesn't cover compounded medications. Compounded semaglutide is a cash-pay option for patients whose Wegovy PA is denied or whose plans exclude weight-loss drugs. FormBlends compounded semaglutide costs $179 to $279 per month without insurance involvement.

Sources

1. Employee Benefit Research Institute. Health Plan Funding Arrangements 2025. EBRI Issue Brief. 2025.
2. Hung A et al. Prior Authorization Approval Rates for GLP-1 Receptor Agonists Across Commercial Payers. Journal of Managed Care & Specialty Pharmacy. 2025;31(3):287-294.
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
4. Novo Nordisk A/S. Annual Report 2025. Novo Nordisk Investor Relations. 2025.
5. Aetna Inc. Clinical Policy Bulletin 0808: Obesity Interventions. Aetna Medical Policy. January 2026.
6. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. CMS. 2024.
7. U.S. Food and Drug Administration. Wegovy Prescribing Information. FDA. Revised 2024.
8. U.S. Food and Drug Administration. Ozempic Prescribing Information. FDA. Revised 2024.
9. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. FDA. Accessed April 2026.
10. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. Updated 2024.
11. Congressional Budget Office. H.R. 1577: Treat and Reduce Obesity Act Cost Estimate. CBO. 2025.
12. GoodRx Research Team. The State of Prior Authorization 2024. GoodRx. 2024.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021;384(11):989-1002.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021;325(14):1414-1425.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Aetna, CVS Caremark, and Aetna Medicare Advantage are registered trademarks of Aetna Inc. and CVS Health Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.